Comparing two pills for moderate to severe psoriasis
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests two oral medications, Apremilast and Methotrexate, to see which works better for people with moderate to severe plaque psoriasis. You must not have taken systemic treatments (pills or shots that work throughout the body) in the last 3 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You must have moderate to severe plaque psoriasis, meaning a score of at least 10 on a standard severity scale (PASI).
- You cannot have taken any systemic psoriasis treatment (pills or injections) in the past 3 months.
- You cannot be pregnant, breastfeeding, or planning to become pregnant.
- You must not have a history of liver or kidney problems.
- You must not have a known allergy to Apremilast or Methotrexate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two systemic medications—methotrexate (a traditional immunosuppressant) and tofacitinib (a newer targeted therapy)—to see which works better for moderate-to-severe plaque psoriasis that hasn't responded well to creams or ointments.
This study compares two oral medications—methotrexate and apremilast—to see which works better for relieving itching in people with psoriasis. If you have psoriasis and bothersome itching, you may be able to join.
This study compares two oral pill treatments—methotrexate and tofacitinib—for people with chronic plaque psoriasis that is moderate to severe and hasn't responded well to creams. The goal is to see which pill works better at clearing skin.
This trial compares two drugs, apremilast and adalimumab, to see which is more effective for people with psoriatic arthritis who have not responded well to methotrexate. It focuses on joint pain, swelling, and skin symptoms.
This study tests a medicine called apremilast (brand name ApoLla) to see how well it works and how safe it is for people with moderate to severe psoriasis. If you have had psoriasis for 6 months or more and have not taken apremilast before, you may be a fit.
This trial tests if methotrexate, a medication that calms the immune system, can help adults with moderate-to-severe eczema that hasn't improved with creams or other treatments. You'll either receive methotrexate or a placebo to see which works better.
Hear when a new Chronic Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.